Download
s00432-021-03550-5.pdf 711,34KB
WeightNameValue
1000 Titel
  • Inflammatory markers in autoimmunity induced by checkpoint inhibitors
1000 Autor/in
  1. Husain, Beate |
  2. Kirchberger, Michael Constantin |
  3. Erdmann, Michael |
  4. Schüpferling, Sabine |
  5. Abolhassani, Amir-Reza |
  6. Fröhlich, Waltraud |
  7. Berking, Carola |
  8. , lucie |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-04-10
1000 Erschienen in
1000 Quellenangabe
  • 147(6):1623-1630
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00432-021-03550-5 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076116/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Immune checkpoint inhibitors (ICI) are highly effective in several cancer entities, but also invoke a variety of immune-related adverse events (irAE). These are mostly reversible, but can be life-threatening or even fatal. Currently, the pathogenesis is not fully understood, but crucial for effective treatment. Prediction and early detection of irAE could be facilitated and treatment optimized if relevant biomarkers and effector mechanisms were better characterized.!##!Methods!#!This study included a total of 45 irAE in patients with metastatic melanoma who were treated with ICI. All patients underwent a complete work-up with exclusion of other causes. Longitudinal blood samples were analyzed for a panel of soluble markers and compared to baseline and to patients who did not experience any irAE. Measurements included LDH, interleukin (IL)-6, IL-1β, IL-17, C-reactive protein (CRP) and tumor necrosis factor (TNF)-alpha as well as tumor markers S100 and melanoma inhibitory activity (MIA).!##!Results!#!During the early onset of irAE increases in serum IL-6 (from mean 24.4 pg/ml at baseline to 51.0 pg/ml; p = 0.003) and CRP (from mean 7.0 mg/l at baseline to 17.7 mg/l; p = 0.001) and a decrease in MIA (from mean 5.4 pg/ml at baseline to 4.8 pg/ml; p = 0.035) were detected. No changes in IL-17 were noted. These effects were observed for irAE of different organ systems.!##!Conclusion!#!Increases of a combination of IL-6 and CRP serum levels can be used for the early detection of irAE and tailored management. Interestingly, changes in MIA serum levels also correlate with irAE onset.
1000 Sacherschließung
lokal Inflammation/blood [MeSH]
lokal Gene Expression Regulation, Neoplastic/immunology [MeSH]
lokal Melanoma
lokal Inflammation/chemically induced [MeSH]
lokal Skin Neoplasms/blood [MeSH]
lokal Skin Neoplasms/drug therapy [MeSH]
lokal Cohort Studies [MeSH]
lokal Uveal Neoplasms/blood [MeSH]
lokal Autoimmunity/genetics [MeSH]
lokal Inflammation/genetics [MeSH]
lokal Male [MeSH]
lokal Immune Checkpoint Inhibitors/adverse effects [MeSH]
lokal Melanoma/pathology [MeSH]
lokal Case-Control Studies [MeSH]
lokal Autoimmunity/drug effects [MeSH]
lokal Uveal Neoplasms/pathology [MeSH]
lokal Diabetes Mellitus, Type 1/blood [MeSH]
lokal Melanoma/drug therapy [MeSH]
lokal Inflammation/immunology [MeSH]
lokal Female [MeSH]
lokal Original Article – Cancer Research
lokal Melanoma/genetics [MeSH]
lokal Adult [MeSH]
lokal Diabetes Mellitus, Type 1/chemically induced [MeSH]
lokal Humans [MeSH]
lokal Neoplasm Metastasis [MeSH]
lokal Uveal Neoplasms/drug therapy [MeSH]
lokal Melanoma/blood [MeSH]
lokal Uveal Neoplasms/genetics [MeSH]
lokal Skin Neoplasms/pathology [MeSH]
lokal Immune checkpoint inhibitors
lokal Immune Checkpoint Inhibitors/therapeutic use [MeSH]
lokal Cytokines
lokal Gene Expression Regulation, Neoplastic/drug effects [MeSH]
lokal Autoimmunity/immunology [MeSH]
lokal Skin Neoplasms/genetics [MeSH]
lokal Endocrine System Diseases/blood [MeSH]
lokal Biomarkers, Tumor/blood [MeSH]
lokal Biomarkers, Tumor/genetics [MeSH]
lokal Germany [MeSH]
lokal Endocrine System Diseases/immunology [MeSH]
lokal Diabetes Mellitus, Type 1/immunology [MeSH]
lokal Immune-related adverse events
lokal Endocrine System Diseases/chemically induced [MeSH]
lokal Immune Checkpoint Inhibitors/pharmacology [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-3273-1014|https://frl.publisso.de/adhoc/uri/S2lyY2hiZXJnZXIsIE1pY2hhZWwgQ29uc3RhbnRpbg==|https://frl.publisso.de/adhoc/uri/RXJkbWFubiwgTWljaGFlbA==|https://frl.publisso.de/adhoc/uri/U2Now7xwZmVybGluZywgU2FiaW5l|https://frl.publisso.de/adhoc/uri/QWJvbGhhc3NhbmksIEFtaXItUmV6YQ==|https://frl.publisso.de/adhoc/uri/RnLDtmhsaWNoLCBXYWx0cmF1ZA==|https://frl.publisso.de/adhoc/uri/QmVya2luZywgQ2Fyb2xh|https://orcid.org/0000-0003-4587-007X
1000 Hinweis
  • DeepGreen-ID: 13dab81a34904fcd94e4aaeb793d92b6 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
  1. Inflammatory markers in autoimmunity induced by checkpoint inhibitors
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6449924.rdf
1000 Erstellt am 2023-05-09T10:37:00.720+0200
1000 Erstellt von 322
1000 beschreibt frl:6449924
1000 Zuletzt bearbeitet 2023-10-21T02:24:33.756+0200
1000 Objekt bearb. Sat Oct 21 02:24:33 CEST 2023
1000 Vgl. frl:6449924
1000 Oai Id
  1. oai:frl.publisso.de:frl:6449924 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source